Niklas Frahm

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Topics

Mass Spectrometry

Respiratory Syndrome Coronavirus

Multiple Sclerosis

Top Venues

Therapeutic advances in neurological disorders

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C Salmen, Ksenija Schirduan, Tom P A Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K Zettl, Melanie Peters, Clemens Warnke
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry. Therapeutic advances in neurological disorders 17 (2024)
Alexander Stahmann, Elaine Craig, David Ellenberger, Firas Fneish, Niklas Frahm, Kathryn C Fitzgerald, Rodden M Middleton, Richard Nicholas, Jeff Rodgers, Clemens Warnke, Salter Amber
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations. Therapeutic advances in neurological disorders 17 (2024)
Alexander Stahmann, Elaine Craig, David Ellenberger, Firas Fneish, Niklas Frahm, Kathryn C Fitzgerald, Rodden M Middleton, Richard Nicholas, Jeff Rodgers, Clemens Warnke, Salter Amber
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations. Therapeutic advances in neurological disorders 17 (2024)
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C Salmen, Ksenija Schirduan, Tom P A Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K Zettl, Melanie Peters, Clemens Warnke
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry. Therapeutic advances in neurological disorders 17 (2024)
Michael Hecker, Niklas Frahm, Uwe Klaus Zettl
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis. Pharmaceutics 16 (1) (2023)
Firas Fneish, Niklas Frahm, Melanie Peters, David Ellenberger, Judith Haas, Micha Löbermann, Dieter Pöhlau, Anna-Lena Röper, Sarah Schilling, Alexander Stahmann, Herbert Temmes, Friedemann Paul, Uwe K Zettl
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study. Vaccines 11 (12) (2023)
Michael Hecker, Niklas Frahm, Uwe Klaus Zettl
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis. Pharmaceutics 16 (1) (2023)
Niklas Frahm, Firas Fneish, David Ellenberger, Judith Haas, Micha Löbermann, Melanie Peters, Dieter Pöhlau, Anna-Lena Röper, Sarah Schilling, Alexander Stahmann, Herbert Temmes, Friedemann Paul, Uwe Klaus Zettl
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study. Journal of clinical medicine 12 (11) (2023)
Firas Fneish, Niklas Frahm, Melanie Peters, David Ellenberger, Judith Haas, Micha Löbermann, Dieter Pöhlau, Anna-Lena Röper, Sarah Schilling, Alexander Stahmann, Herbert Temmes, Friedemann Paul, Uwe K Zettl
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study. Vaccines 11 (12) (2023)
Firas Fneish, David Ellenberger, Niklas Frahm, Alexander Stahmann, Gerhard Fortwengel, Frank Schaarschmidt
Application of Statistical Methods for Central Statistical Monitoring and Implementations on the German Multiple Sclerosis Registry. Therapeutic innovation & regulatory science (2023)
Michael Hecker, Niklas Frahm, Uwe Klaus Zettl
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis. Pharmaceutics 16 (1) (2023)
Felicita Heidler, Julia Baldt, Niklas Frahm, Silvan Elias Langhorst, Pegah Mashhadiakbar, Barbara Streckenbach, Katja Burian, Uwe Klaus Zettl, Jörg Richter
Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. Scientific reports 12 (1) (2022)
Niklas Frahm, Firas Fneish, David Ellenberger, Peter Flachenecker, Friedemann Paul, Clemens Warnke, Christoph Kleinschnitz, Tina Parciak, Dagmar Krefting, Kerstin Hellwig, Judith Haas, Paulus Stefan Rommer, Alexander Stahmann, Uwe K Zettl
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. Neurology and therapy 11 (1) (2022)
Niklas Frahm, Melanie Peters, Jörg Bätzing, David Ellenberger, Manas K Akmatov, Judith Haas, Paulus Stefan Rommer, Alexander Stahmann, Uwe K Zettl, Jakob Holstiege
Prevalence of pediatric multiple sclerosis in Germany: A nationwide population-based analysis. European journal of neurology 28 (9) (2021)
Niklas Frahm, Melanie Peters, Jörg Bätzing, David Ellenberger, Manas K Akmatov, Judith Haas, Paulus Stefan Rommer, Alexander Stahmann, Uwe K Zettl, Jakob Holstiege
Treatment patterns in pediatric patients with multiple sclerosis in Germany-a nationwide claim-based analysis. Therapeutic advances in neurological disorders 14 (2021)
Niklas Frahm, Michael Hecker, Silvan Elias Langhorst, Pegah Mashhadiakbar, Marie-Celine Haker, Uwe Klaus Zettl
The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis. Therapeutic advances in neurological disorders 13 (2020)
Niklas Frahm, Michael Hecker, Uwe Klaus Zettl
Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert opinion on drug safety 19 (2) (2020)
Niklas Frahm, Michael Hecker, Uwe Klaus Zettl
Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. Biology of sex differences 10 (1) (2019)
Niklas Frahm, Michael Hecker, Uwe Klaus Zettl
Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study. PloS one 14 (1) (2019)
Niklas Frahm, Michael Hecker, Uwe Klaus Zettl
Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors. Scientific reports 9 (1) (2019)